Is there any upside left in DAWN stock as it soars 65%?
Day One Biopharmaceuticals (NASDAQ: DAWN) ripped higher on Friday morning after Servier signed a definitive agreement to acquire the California-based firm for about $2.5 billion in cash. Servier’s deal rewrites DAWN’s technical profile, valuing its shares at $21.5 each, which translates to a nearly 70% upside from its previous close. Following this explosive move to
